The UK government has reached agreements it says will give British citizens early access to 90m doses of two more potential Covid-19 vaccines, The Guardian reports.
The vaccines are being developed by the US biotech company Novavax and the pharmaceutical business Janssen, which is owned by Johnson & Johnson and has its headquarters in Belgium.
Under the in-principle agreements, the UK has secured 60m doses of the Novavax vaccine, and is supporting a phase 3 clinical trial with the National Institute for Health Research (NIHR).
Another 30 million doses have been secured from Janssen and ministers have agreed in principle to co-fund a global clinical study of its vaccine.
The agreements, on top of earlier deals, mean the UK has access to six different Covid-19 vaccine candidates in development, across four different types, representing 340 million doses.
